Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high-grade glioma?

Affiliations

Editorial

Jennie W Taylor. Neuro Oncol. 2022.

. 2022 Mar 12;24(3):465-466.

doi: 10.1093/neuonc/noab277.

¹ Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

No abstract available

Comment on

Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
Jo J, Donahue J, Sarai G, Petroni G, Schiff D. Jo J, et al. Neuro Oncol. 2022 Mar 12;24(3):455-464. doi: 10.1093/neuonc/noab198. Neuro Oncol. 2022. PMID: 34383073 Free PMC article.

1. Diaz M, Jo J, Smolkin M, Ratcliffe SJ, Schiff D. Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype. Neurology. 2021;96(7):e1063–e1069. - PMC - PubMed
1. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012;14(suppl 4):iv73–iv80. - PMC - PubMed
1. Jo J, Donahue J, Sarai G, Petroni G, Schiff D. Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk?. Neuro Oncol. 2022;24(3):455–464. - PMC - PubMed
1. Porfidia A, Giordano M, Sturiale CL, et al. . Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: a meta-analysis. Brain Behav. 2020;10(6):e01638. - PMC - PubMed
1. Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017;129(25):3379–3385. - PubMed